ArticleACS omega2026
Accelerated Mucopermeation and Penetration of the Polypeptide Antibiotic Colistin via Ionic Complexation with Polyphosphazene Carriers.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mucus barrier plays a vital protective role for nonkeratinized epithelia in the body, yet its complex structure poses a significant obstacle to effective noninvasive, topical drug delivery. Here, we synthesize chain-end-labeled poly-(α-glutamic acid) (PGA) and poly-[di-(carboxylatophenoxy)-phosphazene] (PCPP) and use an artificial pulmonary mucus to evaluate the mucopermeation of the polymers compared with the established mucus-penetrating polymer poly-(ethylene glycol) (PEG). The biodegradable polyacids PGA and PCPP exhibited mucus permeability similar to that of the biopersistent PEG, even at high polymer concentrations (up to 50 mg/mL). To enable drug loading, PGA and PCPP were further examined for their ability to electrostatically complex the antibiotic lipopeptide Colistin (Polymyxin E) at different polymer-to-Colistin ratios. Colistin binding studies in PBS confirmed effective encapsulation by both polymers with PCPP-Colistin complexes exhibiting the highest stability. Mucopermeation studies of the polymer-Colistin complexes revealed enhanced Colistin mucopermeation for both polyacids, with an enhanced effect observed for PCPP complexes. Furthermore, the broth microdilution assay revealed no differences in the minimum inhibitory concentrations (MICs) of Colistin, PGA-Colistin, or PCPP-Colistin. Overall, PCPP showed significantly superior performance due to its higher Colistin encapsulation efficiency, attributed to its unique chemical structure, thereby highlighting its potential as a biodegradable mucus-penetrating carrier for cationic therapeutic peptides.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.